Companies built from the ground up based on high impact technologies exclusively licensed from top research institutions around the world.
Nob Hill Therapeutics, Inc. commercializes a first-in-kind dry powder nebulizer platform “DryNeb™” for respiratory inhalation drug delivery applications.
SFC Fluidics is a medical device company whose drug delivery platform can dramatically improve therapy compliance in diabetes.
Tesseract Structural Innovations is developing new solutions for vehicle safety through unique structures.
Zebra Analytix is focused on creating game-changing analytical solutions spanning diverse, high-impact applications where rapid detection is essential
Akeso Biomedical is an animal performance and food safety company developing new solutions to improve gut health and treat bacterial infections using a broad-spectrum chemistry.
Ascendant Dx is a bioscience company whose mission is to commercialize disruptive diagnostic technologies aiding identification and treatment for diseases of women and children.
BiologicsMD is developing highly targeted, novel human therapeutics for hair loss diseases and conditions, as well as severe bone disorders.
BlueInGreen (BIG) designs, manufactures and services the most efficient gas dissolution equipment for water and wastewater treatment.
CardioWise offers a new approach to cardiac diagnostics – applying machine learning technology to image processing to create transparent, unbiased, clinical evaluation.
Industry: Nutraceuticals • Product: Perceptiv® over the counter supplement for brain health • Indications: Cognitive decline, Alzheimer’s disease, and dementia
Kalera Medical is developing a disruptive solution for kidney stone removal that is faster, easier, and better for patients, clinicians and hospitals.
OsteoVantage™ is developing bioelectric stimulation technology that is targeted at transforming spine and orthopedics treatments with its proprietary INDOS™ (Induced Osteogenic Stimulation) technology
Vixiar Medical develops non-invasive devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden.
